260 related articles for article (PubMed ID: 17258775)
1. Differentiation of eosinophilic leukemia EoL-1 cells into eosinophils induced by histone deacetylase inhibitors.
Ishihara K; Takahashi A; Kaneko M; Sugeno H; Hirasawa N; Hong J; Zee O; Ohuchi K
Life Sci; 2007 Mar; 80(13):1213-20. PubMed ID: 17258775
[TBL] [Abstract][Full Text] [Related]
2. Possible mechanism of action of the histone deacetylase inhibitors for the induction of differentiation of HL-60 clone 15 cells into eosinophils.
Ishihara K; Hong J; Zee O; Ohuchi K
Br J Pharmacol; 2004 Jul; 142(6):1020-30. PubMed ID: 15210580
[TBL] [Abstract][Full Text] [Related]
3. Mechanism for the decrease in the FIP1L1-PDGFRalpha protein level in EoL-1 cells by histone deacetylase inhibitors.
Ishihara K; Kaneko M; Kitamura H; Takahashi A; Hong JJ; Seyama T; Iida K; Wada H; Hirasawa N; Ohuchi K
Int Arch Allergy Immunol; 2008; 146 Suppl 1():7-10. PubMed ID: 18504399
[TBL] [Abstract][Full Text] [Related]
4. Mechanism for the differentiation of EoL-1 cells into eosinophils by histone deacetylase inhibitors.
Kaneko M; Ishihara K; Takahashi A; Hong J; Hirasawa N; Zee O; Ohuchi K
Int Arch Allergy Immunol; 2007; 143 Suppl 1():28-32. PubMed ID: 17541273
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of the eosinophilic differentiation of HL-60 clone 15 cells induced by n-butyrate.
Ishihara K; Hong J; Zee O; Ohuchi K
Int Arch Allergy Immunol; 2005; 137 Suppl 1():77-82. PubMed ID: 15947489
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha.
Ishihara K; Kitamura H; Hiraizumi K; Kaneko M; Takahashi A; Zee O; Seyama T; Hong J; Ohuchi K; Hirasawa N
Biochem Biophys Res Commun; 2008 Feb; 366(4):1007-11. PubMed ID: 18086564
[TBL] [Abstract][Full Text] [Related]
7. Eosinophil cell lines.
Ishihara K
Methods Mol Biol; 2014; 1178():45-51. PubMed ID: 24986606
[TBL] [Abstract][Full Text] [Related]
8. Cu2+ is required for pyrrolidine dithiocarbamate to inhibit histone acetylation and induce human leukemia cell apoptosis.
Chen J; Du C; Kang J; Wang J
Chem Biol Interact; 2008 Jan; 171(1):26-36. PubMed ID: 17961528
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of histone deacetylation by butyrate induces morphological changes in Y79 retinoblastoma cells.
Karasawa Y; Okisaka S
Jpn J Ophthalmol; 2004; 48(6):542-51. PubMed ID: 15592778
[TBL] [Abstract][Full Text] [Related]
10. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
11. The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines.
Savickiene J; Borutinskaite VV; Treigyte G; Magnusson KE; Navakauskiene R
Eur J Pharmacol; 2006 Nov; 549(1-3):9-18. PubMed ID: 16978604
[TBL] [Abstract][Full Text] [Related]
12. Keratin 23 (K23), a novel acidic keratin, is highly induced by histone deacetylase inhibitors during differentiation of pancreatic cancer cells.
Zhang JS; Wang L; Huang H; Nelson M; Smith DI
Genes Chromosomes Cancer; 2001 Feb; 30(2):123-35. PubMed ID: 11135429
[TBL] [Abstract][Full Text] [Related]
13. Different effects of cyclic AMP and butyrate on eosinophilic differentiation, apoptosis and bcl-2 expression of a human eosinophilic leukemia cell line, EoL-1.
Tai G; Eun-Young J; Yuji H; Masahiko K; Toshio H; Kenji K; Kenshi F; Mitsufumi M
Hematol Oncol; 1996 Dec; 14(4):181-92. PubMed ID: 9267464
[TBL] [Abstract][Full Text] [Related]
14. Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells.
Ueda T; Takai N; Nishida M; Nasu K; Narahara H
Int J Mol Med; 2007 Feb; 19(2):301-8. PubMed ID: 17203205
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
[TBL] [Abstract][Full Text] [Related]
16. CD81, a cell cycle regulator, is a novel target for histone deacetylase inhibition in glioma cells.
Gensert JM; Baranova OV; Weinstein DE; Ratan RR
Neurobiol Dis; 2007 Jun; 26(3):671-80. PubMed ID: 17481908
[TBL] [Abstract][Full Text] [Related]
17. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells.
Rahim R; Strobl JS
Anticancer Drugs; 2009 Sep; 20(8):736-45. PubMed ID: 19584707
[TBL] [Abstract][Full Text] [Related]
18. [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A].
Yoshida M
Tanpakushitsu Kakusan Koso; 2007 Oct; 52(13 Suppl):1788-9. PubMed ID: 18051427
[No Abstract] [Full Text] [Related]
19. Regulation of adipocyte differentiation by histone deacetylase inhibitors.
Kim SN; Choi HY; Kim YK
Arch Pharm Res; 2009 Apr; 32(4):535-41. PubMed ID: 19407971
[TBL] [Abstract][Full Text] [Related]
20. Reduction of telomerase activity in human liver cancer cells by a histone deacetylase inhibitor.
Nakamura M; Saito H; Ebinuma H; Wakabayashi K; Saito Y; Takagi T; Nakamoto N; Ishii H
J Cell Physiol; 2001 Jun; 187(3):392-401. PubMed ID: 11319763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
